Perrigo launches generic Aleve Liquid Gels

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 29 2010Perrigo

Perrigo (Nasdaq: PRGO; TASE) today announced that it has launched Naproxen Sodium Soft Gels. The product is the generic equivalent of Bayer HealthCare's Aleve® Liquid Gels, 220mg, an OTC analgesic.  Aleve® Liquid Gels had sales of approximately $80 million, as measured by Information Resources, Inc. Perrigo believes it is the first to market a store brand version of this product.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval is another example of Perrigo's commitment to bring new products to market. Perrigo is working every day to make quality healthcare more affordable."

Source:

Perrigo

Posted in: Pharmaceutical News

Tags: ,

Comments (0)

Suggested Reading

Navigating the minefield of AI in healthcare: Balancing innovation with accuracy
Study shines light on the well-being challenges faced by women in healthcare
Aster DM Healthcare reveals top foods to combat PCOS symptoms
AI technologies can accurately identify cases of healthcare-associated infections
Emerging trends in wearable breath sensors aim at personalized healthcare solutions
Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting
Can generative AI truly transform healthcare into a more personalized experience?
Millimeter-scale magnetic implants for wireless health monitoring

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New study aims to reduce bias in AI health prediction models